GUTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fractyl Health Inc (GUTS) is not a good buy at this time for a beginner investor with a long-term focus. The stock has weak financials, no significant positive catalysts, and a mixed-to-negative sentiment from analysts. Additionally, there are no strong trading signals or recent influential trades to support a buy decision.
The MACD is above 0 but positively contracting, indicating a lack of strong momentum. RSI is neutral at 49.681, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 0.479, with resistance at 0.517 and support at 0.442.
NULL identified. No recent news or significant positive developments.
Analysts have downgraded the stock and lowered price targets due to disappointing trial data and uncertainty about future performance. Financials show a complete revenue drop and significant losses, despite some improvement in net income and EPS.
In Q3 2025, revenue dropped to 0 (-100% YoY), gross margin fell to 0 (-100% YoY), net income improved to -$45.6M (+96.79% YoY), and EPS increased to -0.71 (+47.92% YoY). Overall, the company is not generating revenue and remains deeply unprofitable.
Analysts have a mixed-to-negative outlook. BofA maintains a Buy rating but lowered the price target to $2 from $5, citing imperfect trial data. Morgan Stanley downgraded the stock to Equal Weight from Overweight, reducing the price target to $2 from $8, citing disappointing trial results and uncertainty about future success.
